Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00227591 · ClinicalTrials.gov registry record · Phase 2
Lenalidomide and Prednisone in Treating Patients With Myelofibrosis
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT00227591: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00227591 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 48 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00227591, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
This phase II trial is studying how well giving lenalidomide together with prednisone works in treating patients with myelofibrosis. Lenalidomide may stop the growth of myelofibrosis by blocking blood flow to the cancer. It may also stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with prednisone may kill more cancer cells.
Interventions
- OTHER laboratory biomarker analysis
- DRUG prednisone
- DRUG lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2005-12 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00227591
The ClinicalTrials.gov registry entry for NCT00227591 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00227591 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00227591 about?
NCT00227591 is a clinical study titled "Lenalidomide and Prednisone in Treating Patients With Myelofibrosis". This phase II trial is studying how well giving lenalidomide together with prednisone works in treating patients with myelofibrosis. Lenalidomide may stop the growth of myelofibrosis by blocking blood flow to the cancer. It may also stimulate the immune system in different ways and stop cancer cells...
What is the current status of trial NCT00227591?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2005-12. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00227591?
The interventions under investigation include: laboratory biomarker analysis (OTHER), prednisone (DRUG), lenalidomide (DRUG).
Who is sponsoring clinical trial NCT00227591?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.